866-997-4948(US-Canada Toll Free)

Malignant Pleural Mesothelioma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Oncology

No. of Pages : 131 Pages

Mesothelioma - Pipeline Review, H1 2014

Summary

Global Markets Directs, Malignant Pleural Mesothelioma - Pipeline Review, H1 2014, provides an overview of the Malignant Pleural Mesotheliomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Malignant Pleural Mesothelioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Malignant Pleural Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Malignant Pleural Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Malignant Pleural Mesothelioma Overview 9
Pipeline Products for Malignant Pleural Mesothelioma - Overview 10
Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis 11
Malignant Pleural Mesothelioma - Therapeutics under Development by Companies 12
Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes 14
Malignant Pleural Mesothelioma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Malignant Pleural Mesothelioma - Products under Development by Companies 18
Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes 19
Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development 20
Boehringer Ingelheim GmbH 20
Biogen Idec Inc. 21
Merck & Co., Inc. 22
Oxford BioMedica plc 23
Novartis AG 24
Pfizer Inc. 25
Bionomics Limited 26
Synta Pharmaceuticals Corp. 27
Morphotek, Inc. 28
Virttu Biologics Limited 29
CanBas Co., Ltd. 30
MolMed S.p.A. 31
Genelux Corporation 32
Polaris Group 33
Verastem, Inc. 34
Malignant Pleural Mesothelioma - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 41
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 50
NGR-hTNF - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
vorinostat - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TroVax - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NGR-hTNF - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
nintedanib - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
dovitinib lactate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
amatuximab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CBP-501 + [cisplatin] + [pemetrexed disodium] - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ADI-PEG20 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
defactinib - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PF-03446962 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
BNC-105-P - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ganetespib - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Allogeneic Tumor Cell Vaccine + [celecoxib] + [cyclophosphamide] - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
HSV-1716 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
BG-00001 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
GL-ONC-1 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Autologous Tumor Cell Vaccine + [celecoxib] - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
MV-NIS Vaccine - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
SS1(dsFv)-PE38 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Allogenic Mesenchymal Stem Cells - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Malignant Pleural Mesothelioma - Recent Pipeline Updates 94
Malignant Pleural Mesothelioma - Dormant Projects 121
Malignant Pleural Mesothelioma - Discontinued Products 122
Malignant Pleural Mesothelioma - Product Development Milestones 123
Featured News & Press Releases 123
Dec 20, 2013: MolMed expands in Russia the Phase II trial of NGR-hTNF for the first line maintenance treatment of pleural mesothelioma 123
Oct 28, 2013: Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma 123
Oct 24, 2013: Verastem Announces Presentations at the 2013 World Conference on Lung Cancer 124
Sep 10, 2013: Verastem Initiates COMMAND: A Registration-Directed Trial of Defactinib in Patients with Mesothelioma 125
Sep 10, 2013: Veristat to Assist on Adaptive Enrichment Trial for Verastems Defactinib in Mesothelioma 126
Aug 27, 2013: Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR Study in Mesothelioma 126
May 20, 2013: Aduro Announces Poster Presentations Of Phase II Pancreatic Cancer And Phase IB Mesothelioma Clinical Trials At ASCO 127
Mar 07, 2013: Oxford BioMedica Announces Initiation of Phase II Collaborative Study For TroVax In Malignant Pleural Mesothelioma 127
Nov 12, 2012: Morphotek's Amatuximab Receives FDA Orphan Drug Designation For Treatment Of Malignant Pleural Mesothelioma 128
Sep 10, 2012: Virttu Biologics Initiates Phase I/II Seprehvir Study In Mesothelioma 129
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 131
Disclaimer 131

List of Table

List of Tables
Number of Products under Development for Malignant Pleural Mesothelioma, H1 2014 10
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 20
Malignant Pleural Mesothelioma - Pipeline by Biogen Idec Inc., H1 2014 21
Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H1 2014 22
Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica plc, H1 2014 23
Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H1 2014 24
Malignant Pleural Mesothelioma - Pipeline by Pfizer Inc., H1 2014 25
Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H1 2014 26
Malignant Pleural Mesothelioma - Pipeline Synta Pharmaceuticals Corp., H1 2014 27
Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H1 2014 28
Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H1 2014 29
Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H1 2014 30
Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H1 2014 31
Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H1 2014 32
Malignant Pleural Mesothelioma - Pipeline by Polaris Group, H1 2014 33
Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H1 2014 34
Assessment by Monotherapy Products, H1 2014 35
Assessment by Combination Products, H1 2014 36
Number of Products by Stage and Target, H1 2014 39
Number of Products by Stage and Mechanism of Action, H1 2014 43
Number of Products by Stage and Route of Administration, H1 2014 46
Number of Products by Stage and Molecule Type, H1 2014 49
Malignant Pleural Mesothelioma Therapeutics - Recent Pipeline Updates, H1 2014 94
Malignant Pleural Mesothelioma - Dormant Projects, H1 2014 121
Malignant Pleural Mesothelioma - Discontinued Products, H1 2014 122

List of Chart

List of Figures
Number of Products under Development for Malignant Pleural Mesothelioma, H1 2014 10
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 16
Assessment by Monotherapy Products, H1 2014 35
Assessment by Combination Products, H1 2014 36
Number of Products by Top 10 Target, H1 2014 37
Number of Products by Stage and Top 10 Target, H1 2014 38
Number of Products by Top 10 Mechanism of Action, H1 2014 41
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 42
Number of Products by Top 10 Route of Administration, H1 2014 45
Number of Products by Stage and Top 10 Route of Administration, H1 2014 46
Number of Products by Top 10 Molecule Type, H1 2014 47
Number of Products by Stage and Top 10 Molecule Type, H1 2014 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *